Glaukos (GKOS) Competitors

$133.16 -0.99 (-0.74%)

Closing price 05/8/2026 03:59 PM Eastern

Extended Trading

$133.52 +0.36 (+0.27%)

As of 05/8/2026 07:43 PM Eastern

GKOS vs. GEHC, PHG, ZBH, SNN, and PEN

Should you be buying Glaukos stock or one of its competitors? The main competitors of Glaukos include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), and Penumbra (PEN). These companies are all part of the "medical equipment" industry.

How does Glaukos compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

GE HealthCare Technologies has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

82.1% of GE HealthCare Technologies shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 0.4% of GE HealthCare Technologies shares are held by insiders. Comparatively, 5.8% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

GE HealthCare Technologies has a net margin of 9.10% compared to Glaukos' net margin of -34.34%. GE HealthCare Technologies' return on equity of 20.46% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.10%	20.46%	5.73%
Glaukos	-34.34%	-6.92%	-5.25%

GE HealthCare Technologies presently has a consensus price target of $80.67, suggesting a potential upside of 27.09%. Glaukos has a consensus price target of $144.42, suggesting a potential upside of 8.45%. Given GE HealthCare Technologies' higher probable upside, equities analysts plainly believe GE HealthCare Technologies is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41
Glaukos	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Glaukos had 2 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 17 mentions for Glaukos and 15 mentions for GE HealthCare Technologies. GE HealthCare Technologies' average media sentiment score of 0.76 beat Glaukos' score of 0.54 indicating that GE HealthCare Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GE HealthCare Technologies	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GE HealthCare Technologies has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$20.63B	1.40	$2.08B	$4.18	15.18
Glaukos	$507.44M	15.41	-$187.69M	-$3.28	N/A

Summary

GE HealthCare Technologies beats Glaukos on 9 of the 17 factors compared between the two stocks.

How does Glaukos compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Koninklijke Philips has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

13.7% of Koninklijke Philips shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 5.8% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Koninklijke Philips has a net margin of 5.49% compared to Glaukos' net margin of -34.34%. Koninklijke Philips' return on equity of 13.51% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	5.49%	13.51%	5.48%
Glaukos	-34.34%	-6.92%	-5.25%

Glaukos has a consensus price target of $144.42, suggesting a potential upside of 8.45%. Given Glaukos' stronger consensus rating and higher probable upside, analysts plainly believe Glaukos is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Glaukos	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Glaukos had 4 more articles in the media than Koninklijke Philips. MarketBeat recorded 17 mentions for Glaukos and 13 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 0.81 beat Glaukos' score of 0.54 indicating that Koninklijke Philips is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	1 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.30	$1.01B	$1.06	25.63
Glaukos	$507.44M	15.41	-$187.69M	-$3.28	N/A

Summary

Glaukos beats Koninklijke Philips on 9 of the 17 factors compared between the two stocks.

How does Glaukos compare to Zimmer Biomet?

Glaukos (NYSE:GKOS) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	15.41	-$187.69M	-$3.28	N/A
Zimmer Biomet	$8.23B	1.93	$705.20M	$3.85	21.36

Zimmer Biomet has a net margin of 9.05% compared to Glaukos' net margin of -34.34%. Zimmer Biomet's return on equity of 13.24% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Zimmer Biomet	9.05%	13.24%	7.28%

In the previous week, Glaukos had 14 more articles in the media than Zimmer Biomet. MarketBeat recorded 17 mentions for Glaukos and 3 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.24 beat Glaukos' score of 0.54 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos currently has a consensus target price of $144.42, suggesting a potential upside of 8.45%. Zimmer Biomet has a consensus target price of $102.80, suggesting a potential upside of 24.99%. Given Zimmer Biomet's higher probable upside, analysts plainly believe Zimmer Biomet is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

Glaukos has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 5.8% of Glaukos shares are owned by insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Zimmer Biomet beats Glaukos on 9 of the 16 factors compared between the two stocks.

How does Glaukos compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Smith & Nephew SNATS currently has a consensus price target of $34.75, suggesting a potential upside of 16.21%. Glaukos has a consensus price target of $144.42, suggesting a potential upside of 8.45%. Given Smith & Nephew SNATS's higher probable upside, research analysts clearly believe Smith & Nephew SNATS is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.40
Glaukos	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Smith & Nephew SNATS has higher revenue and earnings than Glaukos.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A
Glaukos	$507.44M	15.41	-$187.69M	-$3.28	N/A

In the previous week, Glaukos had 12 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 17 mentions for Glaukos and 5 mentions for Smith & Nephew SNATS. Glaukos' average media sentiment score of 0.54 beat Smith & Nephew SNATS's score of 0.44 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Smith & Nephew SNATS has a net margin of 0.00% compared to Glaukos' net margin of -34.34%. Smith & Nephew SNATS's return on equity of 0.00% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Glaukos	-34.34%	-6.92%	-5.25%

Smith & Nephew SNATS has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Comparatively, 5.8% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Glaukos beats Smith & Nephew SNATS on 8 of the 14 factors compared between the two stocks.

How does Glaukos compare to Penumbra?

Glaukos (NYSE:GKOS) and Penumbra (NYSE:PEN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Glaukos has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

Penumbra has a net margin of 11.76% compared to Glaukos' net margin of -34.34%. Penumbra's return on equity of 10.87% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Penumbra	11.76%	10.87%	8.45%

99.0% of Glaukos shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 5.8% of Glaukos shares are held by insiders. Comparatively, 4.2% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Penumbra has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	15.41	-$187.69M	-$3.28	N/A
Penumbra	$1.40B	9.03	$177.69M	$4.52	71.27

In the previous week, Glaukos had 4 more articles in the media than Penumbra. MarketBeat recorded 17 mentions for Glaukos and 13 mentions for Penumbra. Glaukos' average media sentiment score of 0.54 beat Penumbra's score of 0.31 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Glaukos presently has a consensus price target of $144.42, indicating a potential upside of 8.45%. Penumbra has a consensus price target of $361.33, indicating a potential upside of 12.16%. Given Penumbra's higher possible upside, analysts clearly believe Penumbra is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Summary

Glaukos beats Penumbra on 9 of the 17 factors compared between the two stocks.

Get Glaukos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GKOS vs. The Competition

Export

Metric	Glaukos	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$7.88B	$7.16B	$6.25B	$22.98B
Dividend Yield	N/A	1.71%	2.78%	4.01%
P/E Ratio	-40.60	49.10	20.88	28.64
Price / Sales	15.41	56.50	534.05	110.84
Price / Cash	N/A	24.93	43.29	25.08
Price / Book	11.66	5.81	9.98	4.62
Net Income	-$187.69M	$158.34M	$3.54B	$1.07B
7 Day Performance	-5.14%	-0.39%	3.51%	0.46%
1 Month Performance	11.31%	4.88%	4.18%	4.10%
1 Year Performance	48.05%	-0.25%	41.86%	28.49%

Glaukos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GKOS Glaukos	2.0958 of 5 stars	$133.16 -0.7%	$144.42 +8.5%	N/A	$7.88B	$507.44M	N/A	1,094
GEHC GE HealthCare Technologies	4.9228 of 5 stars	$61.00 0.0%	$82.00 +34.4%	N/A	$27.76B	$20.63B	14.59	54,000
PHG Koninklijke Philips	2.0346 of 5 stars	$26.27 +0.4%	N/A	N/A	$25.19B	$20.17B	24.78	65,340	News Coverage Earnings Report
ZBH Zimmer Biomet	3.9451 of 5 stars	$82.73 -0.2%	$102.43 +23.8%	N/A	$16.05B	$8.41B	21.49	17,000	Positive News
SNN Smith & Nephew SNATS	4.0163 of 5 stars	$30.92 -0.8%	$34.75 +12.4%	N/A	$13.30B	$6.16B	N/A	16,988	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GKOS) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Glaukos (GKOS) Competitors

GKOS vs. GEHC, PHG, ZBH, SNN, and PEN

How does Glaukos compare to GE HealthCare Technologies?

Summary

How does Glaukos compare to Koninklijke Philips?

Summary

How does Glaukos compare to Zimmer Biomet?

Summary

How does Glaukos compare to Smith & Nephew SNATS?

Summary

How does Glaukos compare to Penumbra?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS vs. The Competition

Glaukos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Glaukos (GKOS) Competitors

GKOS vs. GEHC, PHG, ZBH, SNN, and PEN

How does Glaukos compare to GE HealthCare Technologies?

Which has more volatility and risk, GEHC or GKOS?

Do insiders and institutionals have more ownership in GEHC or GKOS?

Is GEHC or GKOS more profitable?

Do analysts rate GEHC or GKOS?

Does the media favor GEHC or GKOS?

Which has better valuation and earnings, GEHC or GKOS?

Summary

How does Glaukos compare to Koninklijke Philips?

Which has more volatility and risk, PHG or GKOS?

Do insiders and institutionals have more ownership in PHG or GKOS?

Is PHG or GKOS more profitable?

Do analysts rate PHG or GKOS?

Does the media favor PHG or GKOS?

Which has better valuation and earnings, PHG or GKOS?

Summary

How does Glaukos compare to Zimmer Biomet?

Which has stronger earnings & valuation, GKOS or ZBH?

Is GKOS or ZBH more profitable?

Does the media refer more to GKOS or ZBH?

Do analysts prefer GKOS or ZBH?

Which has more risk & volatility, GKOS or ZBH?

Do institutionals and insiders have more ownership in GKOS or ZBH?

Summary

How does Glaukos compare to Smith & Nephew SNATS?

Do analysts rate SNN or GKOS?

Which has better earnings & valuation, SNN or GKOS?

Does the media prefer SNN or GKOS?

Is SNN or GKOS more profitable?

Which has more volatility & risk, SNN or GKOS?

Do institutionals & insiders hold more shares of SNN or GKOS?

Summary

How does Glaukos compare to Penumbra?

Which has more risk & volatility, GKOS or PEN?

Is GKOS or PEN more profitable?

Do institutionals and insiders hold more shares of GKOS or PEN?

Which has higher valuation and earnings, GKOS or PEN?

Does the media favor GKOS or PEN?

Do analysts prefer GKOS or PEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS vs. The Competition

Glaukos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools